Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (622) Arrow Down
Filter Results: (622) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (622)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)

Show Results For

  • All HBS Web  (622)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)
← Page 12 of 622 Results →
  • Web

Winners & Runners-Up | New Venture Competition

of biotechnology by revolutionizing the water treatment industry with our patented, low cost, environmentally friendly process for water demineralization. Elective Medical Lending Boyd Bishop Simon Mattox Business Track Runner-Up Elective... View Details
  • Profile

Prineeta Kulkarni

Prineeta Kulkarni originally "dreamed of becoming a scientist." She completed a dual biotechnology BS/MS at the University of Pune, but when it came time to launch her career, she shifted direction. "I wanted to see the... View Details
Keywords: Healthcare/Biotech; Nonprofit/Government/Education
  • Web

Climate Impact - Business & Environment

production of next-generation ingredients. We leverage biotechnology as a scalable, sustainable alternative to industrial agriculture and recently launched Palmless , the platform for sustainable palm oil alternatives.” Sarah Wright MBA... View Details
  • 02 Dec 2002
  • Research & Ideas

The Secret of How Microsoft Stays on Top

industry or the biotechnology industry? Both industries share similarities with software, in that firms codify their intellectual property into libraries that can be reused and extended over time. But do we observe the same dynamics in... View Details
Keywords: by Sean Silverthorne
  • 12 Apr 2022
  • Blog Post

The Many Languages of Medicine to Impact Care Delivery

their suffering is extremely compelling and was the catalyst for my pursuit of an MS/MBA in Biotechnology degree. As a joint degree student, I benefit from immersive case studies at HBS where my classmates and I are challenged to analyze... View Details
  • September 2010 (Revised July 2013)
  • Case

Alnylam Pharmaceuticals: Building Value from the IP Estate

By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
  • October 2007 (Revised July 2013)
  • Case

Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech

By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Biotechnology Industry; Biotechnology Industry; San Diego
Citation
Educators
Purchase
Related
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
  • 01 Oct 2021
  • News

From Scholarship to Life-Saving Impact

focused on patients. “Patients and their families are at the center of why I want to be in the biotechnology space,” she concludes. “When you’re working on rare diseases, it’s hard not to feel like you’re making a difference.” View Details
  • 17 Sep 2021
  • Research & Ideas

The Trial of Elizabeth Holmes: Visionary, Criminal, or Both?

Former Theranos employees began testifying this week against Elizabeth Holmes, the once-celebrated biotech’s founder and CEO, in a criminal trial that has Silicon Valley worried. In opening statements last week, federal prosecutors charged that Holmes and the company’s... View Details
Keywords: by Christina Pazzanese, Harvard Gazette; Biotechnology; Biotechnology; Biotechnology
  • January 2001
  • Case

Abgenix and the XenoMouse

By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details
Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry
Citation
Educators
Purchase
Related
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
  • 18 Nov 2002
  • Research & Ideas

Where Morals and Profits Meet: The Corporate Value Shift

information technologies. Recent advances in biotechnology have raised ethical issues that have never before presented themselves. And globalization has given rise to cross-cultural dilemmas that just weren't a major part of the scene in... View Details
Keywords: by Carla Tishler
  • Profile

Lena Licht

biotechnology despite lacking tangible business experience. I’ll be leaving with the confidence that I can now be a business leader and change maker within my industry, and I cannot wait to hit the ground running after graduation! How... View Details
  • November 2020
  • Case

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Biotechnology Industry; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Case 221-031, November 2020.
  • December 2005 (Revised August 2006)
  • Case

Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug

By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Biotechnology Industry; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)

    Tanner Houston

    Keywords: biotechnology; biotechnology; biotechnology
    • Web

    Student Spotlight: 2023 HCC Co-Presidents Reflect on Their Time at HBS and the Current Health Care Systems - Blog: Health Supplement

    technology, and commercialization decision-making in the life sciences. They complemented the case method with applied learning through projects and written assignments–for example, a mock diligence report for a biotechnology company.... View Details
    • January 2014 (Revised June 2015)
    • Case

    Amgen Inc.: Pursuing Innovation and Imitation? (A)

    By: Ian W. Mackenzie
    Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:... View Details
    Keywords: Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States
    Citation
    Educators
    Purchase
    Related
    Mackenzie, Ian W. "Amgen Inc.: Pursuing Innovation and Imitation? (A)." Harvard Business School Case 714-424, January 2014. (Revised June 2015.)
    • April 2023
    • Case

    Drive Capital: A New Road for Venture

    By: Paul A. Gompers and Alicia Dadlani
    Founded by two former Sequoia Capital partners, Columbus-Ohio-based Drive Capital’s mission was to build a world-class venture capital firm in the middle of the U.S., an area historically overlooked by VCs. Drive faced early challenges of attracting investors, sourcing... View Details
    Keywords: Venture Capital; Business Startups; Entrepreneurship; Investment; Business Strategy; Biotechnology Industry; Biotechnology Industry; United States; Ohio
    Citation
    Educators
    Purchase
    Related
    Gompers, Paul A., and Alicia Dadlani. "Drive Capital: A New Road for Venture." Harvard Business School Case 823-056, April 2023.
    • 12 Jun 2018
    • Research & Ideas

    In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?

    portfolios. They examined all companies that held at least one drug patent on the market as of 2003. The researchers focused mainly on small-molecule drugs, not biologics. That’s because of how the compounds are structured chemically. The complicated chemical makeup of... View Details
    Keywords: by Rachel Layne; Health; Pharmaceutical
    • 31 Jan 2014
    • News

    Body, Heal Thyself

    Chien and Derrick Rossi, published a paper in the journal Nature Biotechnology that showed mRNA Therapeutics was capable of stimulating blood vessel growth, repairing damaged heart tissue, and helping a mouse through myocardial... View Details
    Keywords: Maureen Harmon; biotech; Health, Social Assistance; Scientific Research and Development Services
    • ←
    • 12
    • 13
    • …
    • 31
    • 32
    • →
    ǁ
    Campus Map
    Harvard Business School
    Soldiers Field
    Boston, MA 02163
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College.